What is the future for drug development in atherosclerosis and dyslipidaemia?

Expert Opinion on Drug Discovery

Volumn 4, Issue 1, 2009, Pages 1-3

  Suckling, Keith ^a  

^a NONE   (United Kingdom)

Author keywords

Atherosclerosis; Darapladib; Drug development; Dyslipidaemia; Lipoprotein associated phospholipase A2

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTILIPEMIC AGENT; ATORVASTATIN; DARAPLADIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TORCETRAPIB; TRIACYLGLYCEROL;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG INDUSTRY; DRUG MECHANISM; DYSLIPIDEMIA; EXPERIMENTAL PIG; HEART FAILURE; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; INTRAVASCULAR ULTRASOUND; MEDICAL RESEARCH; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 67649106206     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440802623849     Document Type: Review

References (17)

1. Garnier JP. Rebuilding the R&D engine in big pharma. Harv Bus Rev 2008;86:68-6,128
2. Eichler HG, Pignatti F, Flamion B, et al. Balancing early market access to new drugs with the need for benefit/risk data: a mounting dilemma. Nat Rev Drug Discov 2008;7:818-826
3. Grundy SM. Metabolic syndrome pandemic. Arterioscler Thromb Vasc Biol 2008;28:629-636 (Pubitemid 351651324)
4. Available from: http://www.theheart.org/article/908435.do
5. Kontush A, Guerin M, Chapman MJ. Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008;5:329-336 (Pubitemid 351761707)
6. deGoma EM, deGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels: evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199-2211 (Pubitemid 351754991)
7. Singh U, Devaraj S, Jialal I, et al. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol 2008;102:321-325
8. Duivenvoorden R, Nederveen AJ, de GE, et al. Atherosclerosis imaging as a benchmark in the development of novel cardiovasular drugs. Curr Opin Lipidol 2007;18:613-621 (Pubitemid 350098565)
9. Lindsay AC, Choudhury RP. Form to function: current and future roles for atherosclerosis imaging in drug development. Nat Rev Drug Discov 2008;7:517-529 (Pubitemid 351767119)
10. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
11. Roses AD. Pharmacogenetics in drug discovery and development: a translational perspective. Nat Rev Drug Discov 2008;7:807-817
12. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005;25:923-931 (Pubitemid 40627835)
13. Ballantyne C, Cushman M, Psaty B, et al. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007;14:3-11 (Pubitemid 46271373)
14. Wilensky RL, Shi Y, Mohler ER III, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008;14:1059-1066
15. Serruys PW, Garcia-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 2008;118:1172-1182
16. Boekholdt SM, de Winter RJ, Kastelein JJ. Inhibition of lipoprotein-associated phospholipase activity by darapladib: shifting gears in cardiovascular drug development: are antiinflammatory drugs the next frontier? Circulation 2008;118:1120-1122
17. Suckling K. The landscape of drug discovery in atherosclerosis and dyslipidaemia: a survey from patenting activity. Expert Opin Ther Patents 2008;18:473-484 (Pubitemid 351772541)